Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting (Details)

v3.19.1
Segment Reporting (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Mar. 31, 2019
Mar. 31, 2018
Jun. 30, 2018
Segment Reporting Information [Line Items]                  
Revenues – external customers $ 527     $ 78     $ 1,223 $ 353  
Revenues – intersegment 0     0     0 0  
Research and development 1,453     966     3,850 2,944  
General and administrative 2,844     2,605     9,108 7,690  
Operating loss (3,770)     (3,493)     (11,735) (10,281)  
Interest expense (474)     (478)     (1,426) (1,437)  
Interest and other income 20     8     68 28  
Consolidated net loss (4,224) $ (4,470) $ (4,399) (3,963) $ (3,900) $ 3,827 (13,093) (11,690)  
Total assets 35,674     31,034     35,674 31,034 $ 43,083
Fixed assets, net 24,641     25,335     24,641 25,335 25,152
Intangible assets, net 1,423     1,687     1,423 1,687 $ 1,620
Depreciation expense 341,000     341,000     1,065 1,020  
Amortization of intangible assets 92,000     86,000     243 256  
Intersegment Eliminations [Member]                  
Segment Reporting Information [Line Items]                  
Revenues – external customers 0     0     0 0  
Revenues – intersegment (852)     (339)     (2,369) (1,276)  
Research and development (483)     (93)     (1,307) (375)  
General and administrative (369)     (246)     (1,073) (901)  
Operating loss 0     0     0 0  
Interest expense 0     0     0 0  
Interest and other income 0     0     0 0  
Consolidated net loss 0     0     0 0  
Total assets (13,611)     (12,649)     (13,611) (12,649)  
Fixed assets, net 0     0     0 0  
Intangible assets, net 0     0     0 0  
Depreciation expense 0     0     0 0  
Amortization of intangible assets 0     0     0 0  
iBio CDMO [Member] | Operating Segments [Member]                  
Segment Reporting Information [Line Items]                  
Revenues – external customers 0     0     0 37  
Revenues – intersegment 463     16     1,216 322  
Research and development 883     483     2,005 1,449  
General and administrative 2,340     1,885     7,091 5,305  
Operating loss (2,760)     (2,352)     (7,880) (6,395)  
Interest expense (474)     (478)     (1,426) (1,437)  
Interest and other income 3     1     11 5  
Consolidated net loss (3,231)     (2,829)     (9,296) (7,827)  
Total assets 9,572     21,763     9,572 21,763  
Fixed assets, net 24,638     25,329     24,638 25,329  
Intangible assets, net 0     0     0 0  
Depreciation expense 340     340     1,063 1,018  
Amortization of intangible assets 0     0     0 0  
iBio, Inc [Member] | Operating Segments [Member]                  
Segment Reporting Information [Line Items]                  
Revenues – external customers 527     78     1,223 316  
Revenues – intersegment 389     323     1,153 954  
Research and development 1,053     576     3,152 1,870  
General and administrative 873     966     3,090 3,286  
Operating loss (1,010)     (1,141)     (3,866) (3,886)  
Interest expense 0     0     0 0  
Interest and other income 17     7     57 23  
Consolidated net loss (993)     (1,134)     (3,809) (3,863)  
Total assets 39,713     21,920     39,713 21,920  
Fixed assets, net 3     6     3 6  
Intangible assets, net 1,423     1,687     1,423 1,687  
Depreciation expense 1     1     2 2  
Amortization of intangible assets $ 92     $ 86     $ 243 $ 256